Related references
Note: Only part of the references are listed.Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
Anjali Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma
Akihiro Takeshita et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure
Nathalie A. Johnson et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells
A. Takeshita et al.
LEUKEMIA (2009)
Cetuximab, its clinical use and future perspectives
Fernando Rivera et al.
ANTI-CANCER DRUGS (2008)
Durable Complete Responses From Therapy With Combined Epratuzumab and Rituximab Final Results From an International Multicenter, Phase 2 Study in Recurrent, Indolent, Non-Hodgkin Lymphoma
John P. Leonard et al.
CANCER (2008)
The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: Where does it fit?
Ferry A. L. M. Eskens et al.
EUROPEAN JOURNAL OF CANCER (2008)
Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 μl) blood samples
Erwin R. Boghaert et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia
J. F. DiJoseph et al.
LEUKEMIA (2007)
Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
Vicki L. Goodman et al.
CLINICAL CANCER RESEARCH (2007)
Denileukin diftitox as novel targeted therapy for lymphoid malignancies
Bryan Y. Wong et al.
CANCER INVESTIGATION (2007)
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma
JF DiJoseph et al.
CLINICAL CANCER RESEARCH (2006)
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas
RI Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma
JP Leonard et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab
O Lindén et al.
CLINICAL CANCER RESEARCH (2005)
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:: A study by the groupe d'Etude des lymphomes de l'adulte
P Feugier et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22
JF DiJoseph et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
JF DiJoseph et al.
BLOOD (2004)
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results
JP Leonard et al.
CLINICAL CANCER RESEARCH (2004)
Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma
JF DiJoseph et al.
CLINICAL CANCER RESEARCH (2004)
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Expression and function of CD22, a B-cell restricted molecule
JE Moyron-Quiroz et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2002)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
